Search results
Results from the WOW.Com Content Network
Dabrafenib is indicated as a single agent for the treatment of people with unresectable or metastatic melanoma with BRAF V600E mutation. [2] Dabrafenib is indicated, in combination with trametinib, for BRAF V600E-positive unresectable or metastatic melanoma, metastatic non-small cell lung cancer, metastatic anaplastic thyroid cancer, and unresectable or metastatic solid tumors.
Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma [4] [5] and glioma. [ 6 ] [ 7 ] It is a MEK inhibitor drug with anti-cancer activity. [ 8 ]
The overall response rate was 85% in VEN+G arm compared to 71% in GClb arm, p=0.0007. [9] The trial also demonstrated statistically significant improvements in rates of minimal residual disease negativity (less than one CLL cell per 10 4 leukocytes) in bone marrow and peripheral blood. [9] Overall survival data were not mature at this analysis. [9]
Human infectious diseases may be characterized by their case fatality rate (CFR), the proportion of people diagnosed with a disease who die from it (cf. mortality rate).It should not be confused with the infection fatality rate (IFR), the estimated proportion of people infected by a disease-causing agent, including asymptomatic and undiagnosed infections, who die from the disease.
Melanoma has one of the higher survival rates among cancers, with over 86% of people in the UK and more than 90% in the United States surviving more than 5 years. [18] [19] Skin cancer is the most common form of cancer, globally accounting for at least 40% of cancer cases.
Tunlametinib is a pharmaceutical drug for the treatment of cancer. It is an inhbitor of mitogen-activated protein kinase kinase. [1]In China, tunlametinib was approved in 2024 for the treatment of patients with NRAS-mutated advanced melanoma who were previously treated with a PD-1/PD-L1 targeting agent.
Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.
Sugemalimab is a fully human monoclonal antibody that targets the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and possesses immune checkpoint inhibitory and antineoplastic properties. [10]